This is our proudest work yet—a blueprint for rationally designing next-generation cell therapies. Data and methods are fully open-source for academic use and licensable for translation. Out in @nature.com today. www.nature.com/articles/s41...
www.nature.com
CELLFIE, a CRISPR platform for optimizing cell-based immunotherapies, identifies gene knockouts that enhance CAR T cell efficacy using in vitro and in vivo screens.
